Jens Roar Bjerke • 1945 • Oslo • 9 roles • 16 shareholdings

This website uses cookies to enhance the user experience.

Roles

Management

Name	Role	Total operating income	Total equity	Shares
H HUDKLINIKK OSLO AS	Managing Director/CEO	1,206,765	538,300	100 % directly
O OSLO HUDKLINIKK HUDLEGE BJERKE	Managing Director/CEO	-	-	-

Boards

Name	Role	Total operating income	Total equity	Shares
H HUDKLINIKK OSLO AS	Chairman	1,206,765	538,300	100 % directly
O OSLO DERMATOLOGY AS	Chairman	9,446,773	25,512,521	-
O OSLO HUDLEGEKONTOR AS	Chairman	884,300	1,373,537	-
O OSLO DERMATOLOGY AS	Chairman	-	19,798	-
P PDG22 AS	Chairman	686,328	1,235,639	-
T TIGALON HOLDING AS	Chairman	-	475	-
O OSLO HUDKLINIKK HUDLEGE BJERKE	Holder	-	-	-

Last update: Nov 27, 2023

Shares owned by Jens Roar Bjerke

Name	Share class	Total operating income	Total equity	Share
H HUDKLINIKK OSLO AS	Ordinære aksjer	1,206,765	538,300	100 % directly
E ELOPAK ASA	NO0011002586	622,983,000	165,613,000	< 0.01 % directly
A ATLANTIC SAPPHIRE ASA	NO0013249896	6,665,000	2,785,922,000	< 0.01 % directly
O ORKLA ASA	NO0003733800	292,000,000	67,318,000,000	< 0.01 % directly
H HEXAGON PURUS ASA	NO0010904923	157,815,000	3,416,772,000	< 0.01 % directly
S STOREBRAND ASA	NO0003053605	4,981,000,000	32,127,000,000	< 0.01 % directly
N Norsk Hydro ASA	NO0005052605	165,000,000	48,330,000,000	< 0.01 % directly
S SPAREBANK 1 NORD-NORGE	NO0006000801	-	-	< 0.01 % directly
S SALMAR ASA	NO0010310956	836,826,000	10,049,628,000	< 0.01 % directly
M MOWI ASA	NO0003054108	1,913,000,000	3,013,000,000	< 0.01 % directly
E EQUINOR ASA	NO0010096985	72,543,000,000	41,090,000,000	< 0.01 % directly
T TELENOR ASA	NO0010063308	477,000,000	103,796,000,000	< 0.01 % directly
Y YARA INTERNATIONAL ASA	NO0010208051	3,988,000,000	24,619,000,000	< 0.01 % directly
D DNB BANK ASA	NO0010161896	-	-	< 0.01 % directly
G GJENSIDIGE FORSIKRING ASA	NO0010582521	-	-	< 0.01 % directly
B BORREGAARD ASA	NO0010657505	0	2,259,279,000	< 0.01 % directly

Limited to direct ownership positions of 0.5% or more.

Last update: Jun 2, 2025